ROCHESTER, N.Y. — Canadian drugmaker Valeant Pharmaceuticals says it
will buy eye-health company Bausch + Lomb for $8.7 billion in cash in a
massive expansion of its ophthalmology business.
Valeant says the deal will help it capitalize on increasing demand
for contact lenses and other products because of aging populations,
growing demand in emerging markets and increasing rates of diabetes.
Investment firm Warburg Pincus, which leads an investment group that
owns Bausch + Lomb, will receive $4.5 billion in cash. The remaining
$4.2 billion will be used to repay Bausch + Lomb's debt.
Rochester, N.Y.-based Bausch + Lomb Holdings Inc. makes contact lenses, eye drugs and ophthalmic surgical devices.
Bausch + Lomb will keep its name and become a division of Valeant Pharmaceuticals International Inc., based in Laval, Quebec.
Prominent hotel developer and Missouri philanthropist John Q. Hammons
has died. He was 94. His company says Hammons passed away Sunday at the
Springfield nursing home where he'd lived after stepping away from the
company he led well into.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment